Boston Scientific (NYSE:BSX) Sets New 12-Month Low – Here’s Why

Boston Scientific Corporation (NYSE:BSX)’s stock price hit a new 52-week low on Wednesday . The stock traded as low as $45.91 and last traded at $45.9580, with a volume of 6156087 shares traded. The stock had previously closed at $46.92.

Analyst Upgrades and Downgrades

BSX has been the subject of a number of recent research reports. Needham & Company LLC restated a “buy” rating and issued a $77.00 target price on shares of Boston Scientific in a research note on Monday, May 18th. Canaccord Genuity Group lowered their price target on shares of Boston Scientific from $71.00 to $70.00 and set a “buy” rating on the stock in a report on Monday, June 1st. Leerink Partners dropped their price objective on shares of Boston Scientific from $87.00 to $74.00 and set an “outperform” rating for the company in a research note on Thursday, May 28th. Zacks Research lowered shares of Boston Scientific from a “hold” rating to a “strong sell” rating in a research report on Friday, June 5th. Finally, Oppenheimer set a $90.00 target price on shares of Boston Scientific in a research note on Thursday, April 23rd. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Boston Scientific currently has an average rating of “Moderate Buy” and a consensus price target of $85.08.

Boston Scientific Stock Down 3.9%

The company has a quick ratio of 1.22, a current ratio of 1.90 and a debt-to-equity ratio of 0.42. The business has a 50-day simple moving average of $55.74 and a two-hundred day simple moving average of $74.02. The stock has a market capitalization of $67.04 billion, a P/E ratio of 18.91, a PEG ratio of 0.89 and a beta of 0.56.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, beating the consensus estimate of $0.79 by $0.01. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The company had revenue of $5.20 billion for the quarter, compared to the consensus estimate of $5.19 billion. During the same quarter in the previous year, the company earned $0.75 EPS. The firm’s revenue for the quarter was up 11.6% compared to the same quarter last year. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Equities research analysts forecast that Boston Scientific Corporation will post 3.36 earnings per share for the current fiscal year.

Boston Scientific declared that its Board of Directors has initiated a stock repurchase plan on Monday, May 18th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the medical equipment provider to purchase up to 6.4% of its shares through open market purchases. Shares buyback plans are often a sign that the company’s leadership believes its stock is undervalued.

Insider Buying and Selling at Boston Scientific

In other news, Director Edward J. Ludwig acquired 3,580 shares of the firm’s stock in a transaction on Wednesday, May 20th. The shares were purchased at an average cost of $56.68 per share, with a total value of $202,914.40. Following the completion of the purchase, the director owned 25,359 shares of the company’s stock, valued at $1,437,348.12. This represents a 16.44% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director David C. Habiger acquired 2,250 shares of the company’s stock in a transaction dated Wednesday, May 20th. The shares were purchased at an average cost of $55.92 per share, with a total value of $125,820.00. Following the acquisition, the director owned 13,878 shares of the company’s stock, valued at approximately $776,057.76. This represents a 19.35% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have bought a total of 9,800 shares of company stock worth $554,012 over the last ninety days. Corporate insiders own 0.34% of the company’s stock.

Institutional Trading of Boston Scientific

Several large investors have recently made changes to their positions in BSX. FWL Investment Management LLC acquired a new position in Boston Scientific during the 2nd quarter worth about $26,000. Swiss RE Ltd. acquired a new stake in Boston Scientific in the 4th quarter valued at about $26,000. Colonial Trust Co SC raised its stake in shares of Boston Scientific by 502.2% in the third quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 231 shares during the last quarter. Garton & Associates Financial Advisors LLC acquired a new position in shares of Boston Scientific during the fourth quarter worth approximately $26,000. Finally, Bangor Savings Bank lifted its position in shares of Boston Scientific by 94.7% during the fourth quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 142 shares in the last quarter. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.